Media coverage about Onconova Therapeutics (NASDAQ:ONTX) has trended somewhat positive this week, AlphaOne Sentiment reports. The research firm, a service of Accern, scores the sentiment of media coverage by analyzing more than 20 million blog and news sources in real-time. AlphaOne ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Onconova Therapeutics earned a daily sentiment score of 0.13 on AlphaOne’s scale. AlphaOne also assigned news coverage about the biopharmaceutical company an impact score of 0 out of 100, indicating that recent media coverage is extremely unlikely to have an impact on the company’s share price in the next several days.
These are some of the media stories that may have impacted AlphaOne’s rankings:
- Onconova Therapeutics,Inc. (NASDAQ:ONTX) Files An 8-K Submission of Matters to a Vote of Security Holders (4-traders.com)
- Onconova Therapeutics to Present a Poster Session Relating to Intravenous Rigosertib at the 2017 American Society of Clinical Oncology Annual Meeting (finance.yahoo.com)
- Levels in View for Onconova Therapeutics, Inc. (NASDAQ:ONTX) – Lenox Ledger (lenoxledger.com)
- Edited Transcript of ONTX earnings conference call or presentation 15-May-17 1:00pm GMT (finance.yahoo.com)
- Onconova Therapeutics Inc (ONTX) Releases Quarterly Earnings Results, Misses Expectations By $0.27 EPS (americanbankingnews.com)
Shares of Onconova Therapeutics (NASDAQ:ONTX) traded up 3.47% during midday trading on Friday, hitting $2.09. 92,580 shares of the company’s stock traded hands. The stock’s market cap is $14.15 million. Onconova Therapeutics has a 52 week low of $1.95 and a 52 week high of $8.17. The company has a 50 day moving average of $2.43 and a 200 day moving average of $2.63.
Onconova Therapeutics (NASDAQ:ONTX) last issued its quarterly earnings results on Monday, May 15th. The biopharmaceutical company reported ($1.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.96) by $0.27. The business had revenue of $0.21 million for the quarter. Onconova Therapeutics had a negative net margin of 73.67% and a negative return on equity of 148.52%. On average, equities analysts forecast that Onconova Therapeutics will post ($3.30) EPS for the current fiscal year.
Several brokerages have commented on ONTX. Laidlaw began coverage on shares of Onconova Therapeutics in a research report on Thursday, April 27th. They set a “buy” rating and a $10.00 target price on the stock. Maxim Group restated a “buy” rating and set a $6.00 target price on shares of Onconova Therapeutics in a research report on Tuesday, April 4th.
ILLEGAL ACTIVITY WARNING: This news story was first posted by Mideast Time and is the property of of Mideast Time. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at https://www.mideasttime.com/onconova-therapeutics-ontx-receives-daily-media-impact-rating-of-0-13/1708499.html.
In other news, insider Ramesh Kumar bought 23,810 shares of the stock in a transaction that occurred on Wednesday, April 26th. The shares were purchased at an average cost of $2.10 per share, with a total value of $50,001.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director E Premkumar Reddy bought 119,048 shares of the stock in a transaction that occurred on Wednesday, April 26th. The shares were purchased at an average cost of $2.10 per share, for a total transaction of $250,000.80. Following the completion of the acquisition, the director now owns 385,832 shares of the company’s stock, valued at $810,247.20. The disclosure for this purchase can be found here. Insiders have bought 144,287 shares of company stock worth $303,003 over the last three months. Corporate insiders own 27.30% of the company’s stock.
Onconova Therapeutics Company Profile
Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells.
Receive News & Ratings for Onconova Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconova Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.